Question 1

What is Biohaven's business segments — net loss?

Accepted Answer

Biohaven (BHVN) reported business segments — net loss of -$130.53M in Q1 2026.

Question 2

How has Biohaven's business segments — net loss changed year-over-year?

Accepted Answer

Biohaven's business segments — net loss increased by 41.1% year-over-year, from -$221.68M to -$130.53M.

Question 3

What is the long-term trend for Biohaven's business segments — net loss?

Accepted Answer

Over 3 years (2022 to 2025), Biohaven's business segments — net loss has grown at a 9.0% compound annual growth rate (CAGR), from -$570.28M to -$738.82M.

Question 4

What does business segments — net loss mean?

Accepted Answer

Indicates the bottom-line financial result for the reportable segment after all operating expenses, taxes, and non-operating items are deducted. For clinical-stage companies, this metric typically reflects the heavy investment phase of drug development. It serves as the primary measure of the segment's current financial burn rate.

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Other income, net	168	493
Loss before provision for income taxes	(130,260)	(221,068)
Provision for income taxes	272	609
Net loss	$(130,532)	$(221,677)
Net loss per share — basic and diluted	$(0.88)	$(2.17)
Weighted average common shares outstanding—basic and diluted	147,615,197	101,943,396
Comprehensive loss:
Net loss	$(130,532)	$(221,677)

Similar metrics at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Returns & leverage

Where this comes from

FAQ

Ask your AI about Biohaven's business segments — net loss.

Biohaven BHVN Business Segments — Net loss